trial · primary record
TTRNA-DC vaccines with GM-CSF
Recurrent Group 3 Medulloblastoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 12 |
| Primary completion | 2028-12-01 |
| Primary endpoint | Number of participants with immunotherapy-related dose-limiting toxicities after treatment with TTRNA-DCs, TTRNA-xALT and HSCs plus PD1 blockade |
| Registry ID | NCT06514898 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:58.247Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06514898
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- TTRNA-DC vaccines with GM-CSF · compound